Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33721562

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Apr
First author
Kuruvilla J

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Apr;22(4):417-419. doi: 10.1016/S1470-2045(21)00138-8.
    note
    Source null
    related pmid
    33794200
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 May;22(5):e184. doi: 10.1016/S1470-2045(21)00193-5.
    note
    Source null
    related pmid
    33932383
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2021 Jun;22(6):e234. doi: 10.1016/S1470-2045(21)00251-5.
    note
    Source null
    related pmid
    34087143
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2021 Jun;22(6):e235. doi: 10.1016/S1470-2045(21)00290-4.
    note
    Source null
    related pmid
    34087144
    relationship
    Comment in

Authors and identifiers

  1. name
    Kuruvilla J
    type
    Author
  2. name
    Ramchandren R
    type
    Author
  3. name
    Santoro A
    type
    Author
  4. name
    Paszkiewicz-Kozik E
    type
    Author
  5. name
    Gasiorowski R
    type
    Author
  6. name
    Johnson NA
    type
    Author
  7. name
    Fogliatto LM
    type
    Author
  8. name
    Goncalves I
    type
    Author
  9. name
    de Oliveira JSR
    type
    Author
  10. name
    Buccheri V
    type
    Author
  11. name
    Perini GF
    type
    Author
  12. name
    Goldschmidt N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kuruvilla J
    type
    Author
  2. name
    Ramchandren R
    type
    Author
  3. name
    Santoro A
    type
    Author
  4. name
    Paszkiewicz-Kozik E
    type
    Author
  5. name
    Gasiorowski R
    type
    Author
  6. name
    Johnson NA
    type
    Author
  7. name
    Fogliatto LM
    type
    Author
  8. name
    Goncalves I
    type
    Author
  9. name
    de Oliveira JSR
    type
    Author
  10. name
    Buccheri V
    type
    Author
  11. name
    Perini GF
    type
    Author
  12. name
    Goldschmidt N
    type
    Author
bibliography ids
  1. nci-bib-ea198ae2da84f50521b757ff
book metadata
content sha256
8713f1eddb1e25b840e89603261d54d75b485f897235cd3f9e1b6ca762b5566a
document type
citation
dois
  1. 10.1016/S1470-2045(21)00005-X
electronic publication date
display
2021 Mar 12
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33721562
immutable id
pubmed:33721562@8713f1eddb1e25b840e89603261d54d75b485f897235cd3f9e1b6ca762b5566a
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
512-524
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Apr;22(4):417-419. doi: 10.1016/S1470-2045(21)00138-8.
    note
    Source null
    related pmid
    33794200
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 May;22(5):e184. doi: 10.1016/S1470-2045(21)00193-5.
    note
    Source null
    related pmid
    33932383
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2021 Jun;22(6):e234. doi: 10.1016/S1470-2045(21)00251-5.
    note
    Source null
    related pmid
    34087143
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2021 Jun;22(6):e235. doi: 10.1016/S1470-2045(21)00290-4.
    note
    Source null
    related pmid
    34087144
    relationship
    Comment in
outcomes validated
false
pmid
33721562
provenance
batch id
79f1021053e858d13ff3
provider
NCBI PubMed ESummary
record sha256
60bd65ae592e33801b50e15c3af2b455a3360d3ae646a511164ad7b10e9c4456
response sha256
671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
retrieved at
2026-09-09T23:47:59.098265+00:00
publication date
display
2021 Apr
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33721562/
title
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.

Preserved source evidence · Not medical advice